For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the emergence of Tafamidis and Attruby represents a genuine change. These innovative therapies preserve the transthyretin protein, halting its destructive build-up and lessening the severity of the disease . Individuals are now experiencing positive